Literature DB >> 25070875

Effects of cell-type-specific expression of a pan-caspase inhibitor on renal fibrogenesis.

Tsutomu Inoue1,2, Takeru Kusano2,3, Kouji Tomori1, Hidetomo Nakamoto3, Hiromichi Suzuki1,2, Hirokazu Okada4,5,6.   

Abstract

BACKGROUND: The caspase family of enzymes is grouped into two major sub-families, namely apoptotic and inflammatory caspases, which play central roles in the induction of apoptosis, regulation of inflammation and immunity, and cellular differentiation.
METHODS: The role of caspase activation in tubular epithelium and interstitial cells of 3 lines of transgenic mice with obstructed nephropathy was examined: p35 mice bearing the pan-caspase inhibitor protein expressed by the p35 gene separated from the universal CAG promoter by a floxed STOP sequence were crossed with γGT.Cre and FSP1.Cre mice that express Cre recombinase in the cortical tubular epithelium and FSP1(+) interstitial cells, respectively. The γGT.Cre;p35, FSP1.Cre;p35 and p35 control mice were then challenged with unilateral ureter obstruction (UUO).
RESULTS: Proinflammatory parameters such as protein levels of active IL-1β subunit and mRNA levels of TNF-α and NOD-like receptor pyrin domain containing-3, and profibrogenic parameters such as interstitial matrix deposition and mRNA levels of fibronectin EIIIA isoform and α1 chain of procollagen type I in the kidneys were significantly increased at 7 days in the FSP1.Cre;p35- and p35-UUO mice, but not in the γGT.Cre;p35-UUO mice. These changes paralleled the numbers of apoptotic nuclei in tubules, but not in interstitial cells, and the protein levels of active caspase-3 subunit in the kidneys of FSP1.Cre;p35-, p35- and γGT.Cre;p35-UUO mice.
CONCLUSION: This study provides evidence of the critical role of caspase activation in the tubular epithelium, but not in FSP1(+) interstitial cells, in apoptosis and inflammasome induction, leading to proinflammatory and profibrogenic processes in fibrous kidneys with UUO.

Entities:  

Keywords:  Apoptosis; Caspase; Fibrogenesis; Inflammasome; Inflammation; p35

Mesh:

Substances:

Year:  2014        PMID: 25070875     DOI: 10.1007/s10157-014-1011-0

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  43 in total

1.  Conditional abatement of tissue fibrosis using nucleoside analogs to selectively corrupt DNA replication in transgenic fibroblasts.

Authors:  M Iwano; A Fischer; H Okada; D Plieth; C Xue; T M Danoff; E G Neilson
Journal:  Mol Ther       Date:  2001-02       Impact factor: 11.454

Review 2.  Endothelial apoptosis and chronic transplant vasculopathy: recent results, novel mechanisms.

Authors:  J-F Cailhier; P Laplante; M-J Hébert
Journal:  Am J Transplant       Date:  2006-02       Impact factor: 8.086

3.  TNF-alpha neutralization ameliorates obstruction-induced renal fibrosis and dysfunction.

Authors:  K K Meldrum; R Misseri; P Metcalfe; C A Dinarello; K L Hile; D R Meldrum
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2006-12-14       Impact factor: 3.619

4.  Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice.

Authors:  Takahiro Kodama; Tetsuo Takehara; Hayato Hikita; Satoshi Shimizu; Minoru Shigekawa; Hinako Tsunematsu; Wei Li; Takuya Miyagi; Atsushi Hosui; Tomohide Tatsumi; Hisashi Ishida; Tatsuya Kanto; Naoki Hiramatsu; Satoshi Kubota; Masaharu Takigawa; Yoshito Tomimaru; Akira Tomokuni; Hiroaki Nagano; Yuichiro Doki; Masaki Mori; Norio Hayashi
Journal:  J Clin Invest       Date:  2011-07-11       Impact factor: 14.808

5.  Endogenous ligands for TLR2 and TLR4 are not involved in renal injury following ureteric obstruction.

Authors:  Paramit Chowdhury; Steven Howard Sacks; Neil Stephen Sheerin
Journal:  Nephron Exp Nephrol       Date:  2010-04-28

6.  The inflammasome activating caspase 1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis.

Authors:  Carol M Artlett; Sihem Sassi-Gaha; Judy L Rieger; Alina C Boesteanu; Carol A Feghali-Bostwick; Peter D Katsikis
Journal:  Arthritis Rheum       Date:  2011-11

7.  Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype.

Authors:  Susan K Mathai; Mridu Gulati; Xueyan Peng; Thomas R Russell; Albert C Shaw; Ami N Rubinowitz; Lynne A Murray; Jonathan M Siner; Danielle E Antin-Ozerkis; Ruth R Montgomery; Ronald A S Reilkoff; Richard J Bucala; Erica L Herzog
Journal:  Lab Invest       Date:  2010-04-19       Impact factor: 5.662

8.  Inhibition of apoptosis induced by ischemia-reperfusion prevents inflammation.

Authors:  M A Daemen; C van 't Veer; G Denecker; V H Heemskerk; T G Wolfs; M Clauss; P Vandenabeele; W A Buurman
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

9.  Inflammasome-independent NLRP3 augments TGF-β signaling in kidney epithelium.

Authors:  Wenjie Wang; Xiangyu Wang; Justin Chun; Akosua Vilaysane; Sharon Clark; Gabrielle French; Nathan A Bracey; Kiril Trpkov; Shirin Bonni; Henry J Duff; Paul L Beck; Daniel A Muruve
Journal:  J Immunol       Date:  2012-12-21       Impact factor: 5.422

10.  Identification and characterization of a fibroblast marker: FSP1.

Authors:  F Strutz; H Okada; C W Lo; T Danoff; R L Carone; J E Tomaszewski; E G Neilson
Journal:  J Cell Biol       Date:  1995-07       Impact factor: 10.539

View more
  2 in total

1.  Asbestos-Induced Mesothelial to Fibroblastic Transition Is Modulated by the Inflammasome.

Authors:  Joyce K Thompson; Maximilian B MacPherson; Stacie L Beuschel; Arti Shukla
Journal:  Am J Pathol       Date:  2017-01-03       Impact factor: 4.307

Review 2.  Cell death-based approaches in treatment of the urinary tract-associated diseases: a fight for survival in the killing fields.

Authors:  Diego Martin-Sanchez; Miguel Fontecha-Barriuso; Maria Dolores Sanchez-Niño; Adrian M Ramos; Ramiro Cabello; Carmen Gonzalez-Enguita; Andreas Linkermann; Ana Belén Sanz; Alberto Ortiz
Journal:  Cell Death Dis       Date:  2018-01-25       Impact factor: 8.469

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.